Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Microenvironment in BCC Following PDT
NCT05020912Phase 2Active, not recruiting
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Dec 2021
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aminolevulinic acid 10% gel in basal cell carcinoma (BCC), sponsored by Case Comprehensive Cancer Center. Started Dec 2021; status: active, not recruiting.
02
Drugs
aminolevulinic acid 10% gel
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT05020912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05020912.